Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.04-7.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.43% | -27.69% | -7.70% | -29.74% | -36.68% |
| Total Depreciation and Amortization | 2.71% | 15.10% | 25.49% | 72.88% | 22.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 751.33% | -305.45% | -83.92% | 7.89% | 411.29% |
| Change in Net Operating Assets | -82.49% | 244.56% | -8.27% | 304.46% | -33.54% |
| Cash from Operations | -57.66% | 8.39% | -19.09% | 7.96% | -29.12% |
| Capital Expenditure | 98.82% | -1,944.58% | 110.77% | -531.97% | 26.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.86% | -2,004.82% | 101.41% | -4,740.98% | 26.06% |
| Total Debt Issued | -3.31% | 447.24% | -104.32% | -- | -- |
| Total Debt Repaid | -3,718.18% | 35.29% | -- | -- | -- |
| Issuance of Common Stock | 100.50% | -14.97% | 24.07% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -602.06% | 200.00% | 88.41% | -- | -- |
| Cash from Financing | 40.92% | 56.89% | -75.89% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.66% | 19.54% | -163.83% | 152.58% | -7,582.35% |